Approved indications: Sublingual buprenorphine (alone or combined with naloxone) is FDA-approved for induction and maintenance treatment of opioid use disorder (also called opioid dependence) as part of a comprehensive plan that includes counseling and psychosocial support.

Off-label uses: Clinicians sometimes use sublingual buprenorphine off label for chronic pain or for patients with both opioid use disorder and significant pain when other options are ineffective or unsafe, although pain-specific buprenorphine formulations (patch, buccal film) are usually preferred and evidence for high-dose sublingual use purely for pain is more limited.

Efficacy expectations: Withdrawal and craving typically improve within hours of the first properly timed dose and stabilize over several days, with maintenance treatment associated with markedly better retention in care, fewer relapses to illicit opioids, and reduced overdose and mortality compared with no medication. In head-to-head and comparative studies, buprenorphine is similarly effective to methadone for many patients when dosed adequately, though very high–tolerance patients may respond better to higher-dose methadone, and buprenorphine generally has a more favorable safety profile than full opioid agonists and can be at least as effective as extended-release naltrexone for those who are able to complete detoxification before starting treatment.

Typical dosing ranges and schedules: For opioid use disorder in adults (and some adolescents ≥16 years, depending on product), treatment usually starts when mild to moderate withdrawal has begun, with an initial 2–4 mg sublingual dose, followed by additional small doses on day 1 to reach about 8–12 mg, then titrated over several days to an individualized maintenance dose often in the 8–24 mg/day range (many stabilize near 16 mg/day). Dosing is usually once daily, though some stable patients may use split or less frequent dosing if directed by their clinician.

How to take sublingual buprenorphine: Place the tablet or film under the tongue (not on top of the tongue) and allow it to completely dissolve without chewing, crushing, or swallowing it whole, and avoid eating, drinking, smoking, or talking until dissolved. If more than one piece is prescribed, place them under the tongue at the same time or as directed, spreading them out so they do not overlap excessively. Take the medicine at the same time each day, with or without food, and do not change the dose or stop suddenly without medical guidance.

Special instructions, missed doses, and overdose: To reduce the risk of precipitated withdrawal, induction should occur at least about 12 hours after the last short‑acting opioid (e.g., heroin, many pain pills) and 24–36 hours or longer after some long‑acting opioids or methadone, waiting for clear withdrawal symptoms to appear. If you miss a dose, take it as soon as you remember unless it is close to the time of the next dose—in that case, skip the missed dose and resume the regular schedule without doubling. In suspected overdose (very slow or stopped breathing, unable to wake, blue lips or fingertips), call emergency services immediately, administer naloxone if available, and stay with the person until help arrives.

Common side effects (usually mild to moderate): These may include headache, nausea, vomiting, constipation, abdominal pain, sweating, flushing, insomnia, fatigue, dizziness, drowsiness, and mouth or tongue discomfort or numbness with films or tablets. Many effects lessen over days to weeks; constipation, sweating, and mild sleep disturbance may persist and often require simple management (hydration, fiber, stool softeners, adjusting dose timing).

Serious or rare adverse effects needing immediate medical attention: Seek urgent help for very slow or difficult breathing, extreme sleepiness or inability to wake up, confusion, fainting, chest pain, seizures, severe allergic reactions (swelling of face/lips/tongue, trouble breathing, hives), severe or worsening liver problems (yellowing of skin or eyes, dark urine, severe fatigue, right‑upper‑abdominal pain), or signs of adrenal insufficiency (profound fatigue, dizziness, nausea, abdominal pain). Starting too soon after other opioids can cause precipitated withdrawal—sudden, intense withdrawal symptoms—which also requires prompt medical review.

Warnings and precautions: Combining buprenorphine with alcohol, benzodiazepines, sleep medicines, other opioids, or sedating drugs greatly increases the risk of life‑threatening respiratory depression—such combinations should be avoided or used only with very close medical supervision. Use with caution in people with breathing disorders (COPD, sleep apnea), head injury, seizures, low blood pressure, severe liver disease (often avoided if liver failure is present), or significant heart rhythm problems. In pregnancy, buprenorphine is a standard treatment for opioid use disorder and is generally continued because it reduces relapse and overdose risk; newborns may develop neonatal opioid withdrawal syndrome and should be monitored. During breastfeeding, buprenorphine passes into milk at low levels and may be acceptable in many cases with infant monitoring for excessive sleepiness or poor feeding.

Relative safety compared with other opioids: As a partial agonist with a ceiling effect on respiratory depression, buprenorphine has a lower overdose risk than full agonists like heroin, fentanyl, or high-dose methadone when used as prescribed, but it is still an opioid that can be abused, can cause dependence, and can be fatal in overdose, especially with other depressants.

Reporting side effects and staying updated: Patients and caregivers can report side effects directly to the FDA MedWatch program (online or by calling 1-800-FDA-1088), and up-to-date safety communications are available through FDA and product Medication Guides; any new or worsening symptoms should also be discussed promptly with the prescribing clinician.

Major drug and substance interactions: Combining buprenorphine with other central nervous system depressants—such as benzodiazepines (e.g., alprazolam, clonazepam), sleep aids, other opioids, muscle relaxants, gabapentinoids, or alcohol—greatly increases the risk of dangerous sedation and respiratory depression. Strong CYP3A4 inhibitors (such as some antifungals and certain antibiotics or HIV medicines) can raise buprenorphine levels, while CYP3A4 inducers (such as rifampin, carbamazepine, phenytoin, or St John’s wort) can lower levels and reduce effect; doses may need adjustment with close monitoring. Using other opioids while on buprenorphine can lead either to precipitated withdrawal (if buprenorphine displaces them) or overdose (if someone attempts to override buprenorphine’s blocking effect with large doses).

Conditions and co-medications requiring caution: Extra care is needed in people with moderate liver impairment, significant lung disease or sleep apnea, low blood pressure, heart rhythm problems or a history of prolonged QT interval, seizure disorders, or adrenal or thyroid problems. Elderly or frail patients, and those with multiple sedating medications, may be more sensitive to breathing and blood pressure effects. Before surgery, anesthesia, or imaging procedures requiring sedation, patients should tell all clinicians they are taking buprenorphine so perioperative and pain plans can be adjusted safely.

Monitoring needs: Clinicians often monitor liver function tests, assess for signs of sedation, respiratory depression, or adrenal or hormonal changes, and review other medications regularly for interactions. Ongoing follow-up commonly includes monitoring blood pressure and mental status, checking urine drug tests to support treatment goals, tracking cravings and withdrawal, and, when indicated, obtaining electrocardiograms (ECGs) in patients with significant cardiac risk or on other QT‑prolonging drugs.

Q: How long will I need to stay on sublingual buprenorphine?
A: Treatment length is individualized; many people stay on buprenorphine for years because it continues to reduce cravings, relapse, and overdose risk, and decisions about tapering are made gradually with the prescriber based on stability, supports, and patient preference.

Q: Will buprenorphine get me “high” like other opioids?
A: When taken as prescribed by someone with opioid dependence, buprenorphine mainly relieves withdrawal and cravings and usually does not produce the same level of euphoria as full opioids, though some people feel mild mood or energy changes, especially early in treatment.

Q: Can I drive or work while taking buprenorphine?
A: Many patients are able to drive and work once they are on a stable dose, but you should avoid driving, operating machinery, or doing risky tasks until you know how the medicine affects you and after any dose changes or when using other sedating medications.

Q: What happens if I slip and use opioids while on buprenorphine?
A: Some or all of the effects of other opioids may be blocked or blunted, but overdose is still possible—especially if you take large amounts or use potent opioids like fentanyl—so you should contact your treatment team promptly and continue medications and counseling rather than stopping buprenorphine on your own.

Q: Is buprenorphine safe during pregnancy and breastfeeding?
A: Buprenorphine is a standard, evidence-based treatment for opioid use disorder in pregnancy and is usually continued because it lowers relapse and overdose risk; babies should be monitored for neonatal withdrawal, and breastfeeding is often allowed with close observation of the infant, based on shared decision-making with obstetric and pediatric clinicians.

Storage: Store sublingual buprenorphine at room temperature, away from heat, moisture, and direct light, in the original blister pack or container with the child-resistant closure, and always keep it locked away and out of sight and reach of children, teens, and pets.

Disposal: Because it is a high-risk opioid, promptly dispose of unused or expired doses through a drug take-back program or authorized collection site when possible; if no take-back option is readily available, follow FDA guidance, which allows flushing buprenorphine products down the toilet to reduce the risk of accidental ingestion or misuse, and never share this medicine with anyone.